<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02741076</url>
  </required_header>
  <id_info>
    <org_study_id>2065-5</org_study_id>
    <nct_id>NCT02741076</nct_id>
  </id_info>
  <brief_title>Structured Discontinuation vs Continued Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioids for Chronic Pain</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Structured Opioid Discontinuation Versus Continued Opioid Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioid Analgesic Therapy for Chronic Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Member Companies of the Opioid PMR Consortium</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Member Companies of the Opioid PMR Consortium</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect on pain intensity (PI) of structured
      discontinuation of long-term opioid analgesic therapy compared to continuation of opioid
      therapy in Suboptimal and Optimal Responders to high-dose, long-term opioid analgesic therapy
      for chronic low back pain (CLBP).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the mean Average Pain Intensity (PI) score on the 0-10 Numerical Ratings Scale (NRS)</measure>
    <time_frame>From baseline to the 1 week period prior to the Week 12 visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Average Pain Intensity (PI) score on the 0-10 Numerical Ratings Scale (NRS) over 1 week prior to each visit.</measure>
    <time_frame>Weeks 4, 8, 16, 20, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients whose Pain Intensity (PI) score has improved since baseline.</measure>
    <time_frame>Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in physical function (RMDQ)</measure>
    <time_frame>Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Worst Pain Intensity (PI) score on the 0-10 Numerical Ratings Scale over 1 week prior to each visit</measure>
    <time_frame>Weeks 4, 8, 16, 20, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients whose Pain Intensity (PI) score has worsened since baseline.</measure>
    <time_frame>Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on impact of pain on function (BPI-SF)</measure>
    <time_frame>Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on pain quality (PQAS)</measure>
    <time_frame>Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on pain spread (Regional Pain Scale)</measure>
    <time_frame>Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on sleep quality (MOS Sleep Scale)</measure>
    <time_frame>Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on mood (PHQ-8)</measure>
    <time_frame>Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on quality of life (EQ-5D-5L)</measure>
    <time_frame>Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on work productivity (WPAI)</measure>
    <time_frame>Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">820</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <condition>Opiate Addiction</condition>
  <condition>Narcotic Abuse</condition>
  <condition>Drug Abuse</condition>
  <arm_group>
    <arm_group_label>Suboptimal Responders, continuation arm - Morphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suboptimal responders to high-dose opioid therapy that will receive ER opioid tablets + placebo tablets during tapering to maintain the blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suboptimal Responders, discontinuation arm - Morphine Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suboptimal responders to high-dose opioid therapy that will receive matching placebo tablets for the ER opioid + ER opioid tablets only during the first 3-4 weeks after randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Responders, continuation arm - Morphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal responders to high-dose opioid therapy that will receive ER opioid tablets + placebo tablets during tapering to maintain the blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Responders, discontinuation arm - Morphine Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal responders to high-dose opioid therapy that will receive matching placebo tablets for the ER opioid + ER opioid tablets only during the first 3-4 weeks after randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suboptimal Responders, continuation arm - Oxycodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suboptimal responders to high-dose opioid therapy that will receive ER opioid tablets + placebo tablets during tapering to maintain the blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suboptimal Responders, continuation arm - Oxymorphone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suboptimal responders to high-dose opioid therapy that will receive ER opioid tablets + placebo tablets during tapering to maintain the blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suboptimal Responders, discontinuation arm - Oxycodone Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suboptimal responders to high-dose opioid therapy that will receive matching placebo tablets for the ER opioid + ER opioid tablets only during the first 3-4 weeks after randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suboptimal Responders discontinuation arm-Oxymorphon Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suboptimal responders to high-dose opioid therapy that will receive matching placebo tablets for the ER opioid + ER opioid tablets only during the first 3-4 weeks after randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Responders, continuation arm - Oxycodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal responders to high-dose opioid therapy that will receive ER opioid tablets + placebo tablets during tapering to maintain the blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Responders, continuation arm - Oxymorphone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal responders to high-dose opioid therapy that will receive ER opioid tablets + placebo tablets during tapering to maintain the blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Responders, discontinuation arm - Oxycodone Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal responders to high-dose opioid therapy that will receive matching placebo tablets for the ER opioid + ER opioid tablets only during the first 3-4 weeks after randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Responders, discontinuation arm - Oxymorphone Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal responders to high-dose opioid therapy that will receive matching placebo tablets for the ER opioid + ER opioid tablets only during the first 3-4 weeks after randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Sulfate ER</intervention_name>
    <arm_group_label>Suboptimal Responders, continuation arm - Morphine</arm_group_label>
    <arm_group_label>Suboptimal Responders, discontinuation arm - Morphine Placebo</arm_group_label>
    <arm_group_label>Optimal Responders, continuation arm - Morphine</arm_group_label>
    <arm_group_label>Optimal Responders, discontinuation arm - Morphine Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone ER</intervention_name>
    <arm_group_label>Suboptimal Responders, continuation arm - Oxycodone</arm_group_label>
    <arm_group_label>Suboptimal Responders, discontinuation arm - Oxycodone Placebo</arm_group_label>
    <arm_group_label>Optimal Responders, continuation arm - Oxycodone</arm_group_label>
    <arm_group_label>Optimal Responders, discontinuation arm - Oxycodone Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxymorphone ER</intervention_name>
    <arm_group_label>Suboptimal Responders, continuation arm - Oxymorphone</arm_group_label>
    <arm_group_label>Suboptimal Responders discontinuation arm-Oxymorphon Placebo</arm_group_label>
    <arm_group_label>Optimal Responders, continuation arm - Oxymorphone</arm_group_label>
    <arm_group_label>Optimal Responders, discontinuation arm - Oxymorphone Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be male or non-pregnant, non-lactating female aged 18 to 75 years, inclusive.

          2. Have a clinical diagnosis of non-radicular CLBP (pain that occurs in an area with
             boundaries between the lowest rib and the crease of the buttocks) of Class 1 or
             proximal radicular (above the knee) pain of Class 2 based on the Quebec Task Force
             Classification for Spinal Disorders (subjects with previous surgery or chronic pain
             syndrome, i.e., classes 9.2 or 10, will be allowed if their pain does not radiate or
             radiates only proximally) for a minimum of 12 months and

               1. For the Suboptimal Responder group, pain must have been present for at least
                  several hours a day and have an Average PI score of 6-9 on an 11-point NRS within
                  the past 24 hours of screening.

               2. For the Optimal Responder group, subjects must have an Average PI score of 1-4 on
                  an 11-point NRS within the past 24 hours of screening.

          3. Have been taking ER/LA opioids or immediate release opioids (at least 4 times at day)
             for at least 12 months.

          4. Have been taking one of the 3 index ER opioid drugs around-the-clock at a twice-a-day
             frequency for at least 3 consecutive months at a total daily dose within the range
             shown below.

             Daily Dose Range

               1. Morphine sulfate extended-release: 120-540mg

               2. Oxycodone extended-release: 80-360mg

               3. Oxymorphone extended-release: 40-180mg

          5. Be considered, in the opinion of the Investigator, to be in generally good health
             other than CLBP at screening based upon the results of a medical history, physical
             examination, 12-lead ECG, and laboratory profile.

          6. Speak, read, write, and understand English (to reduce heterogeneity of data),
             understand the consent form, and be able to effectively communicate with the study
             staff.

          7. Have access to the Internet (to access the patient support program).

          8. Voluntarily provide written informed consent.

          9. Be willing and able to complete study procedures.

        Exclusion Criteria:

          1. Have any clinically significant condition that would, in the opinion of the
             Investigator, preclude study participation or interfere with the assessment of pain
             and other symptoms of CLBP or increase the risk of opioid-related AEs.

          2. Have a primary diagnosis of fibromyalgia, complex regional pain syndrome, neurogenic
             claudication due to spinal stenosis, spinal cord compression, acute nerve root
             compression, severe or progressive lower extremity weakness or numbness, bowel or
             bladder dysfunction as a result of cauda equina compression, diabetic amyotrophy,
             meningitis, diskitis, back pain because of secondary infection or tumor, or pain
             caused by a confirmed or suspected neoplasm.

          3. Have undergone a surgical procedure for back pain within 6 months prior to the
             Screening Visit.

          4. Have had a nerve or plexus block, including epidural steroid injections or facet
             blocks, within 1 month prior to the Screening Visit or botulinum toxin injection in
             the lower back region within 3 months prior to screening.

          5. Have a history of confirmed malignancy within past 2 years, with exception of basal
             cell or squamous cell carcinoma of the skin that has been successfully treated.

          6. Have uncontrolled blood pressure, i.e., subject has a sitting systolic blood pressure
             &gt;180 mm Hg or &lt;90 mm Hg, or a sitting diastolic blood pressure &gt;110 mmHg or &lt;40 mm Hg
             at screening.

          7. Have a body mass index (BMI) &gt;45 kg/m2. Anyone with a BMI &gt;40 but &lt;45 with complete a
             screening tool (STOPBang Questionnaire) to rule out high risk of obstructive sleep
             apnea.

          8. Have clinically significant depression based on a score of ≥20 on the Patient Health
             Questionnaire (PHQ-8)

          9. Have suicidal ideation associated with actual intent and a method or plan in the past
             year: &quot;Yes&quot; answers on items 4 or 5 of the Columbia-Suicide Severity Rating Scale
             (C-SSRS).

         10. Have a previous history of suicidal behaviors in the past 5 years: &quot;Yes&quot; answer (for
             events that occurred in the past 5 years) to any of the suicidal behavior items of the
             C-SSRS.

         11. Have any lifetime history of serious or recurrent suicidal behavior. (Non-suicidal
             self-injurious behavior is not a trigger for a risk assessment unless in the
             Investigator's judgment it is indicated.)

         12. Have clinically significant abnormality in clinical chemistry, hematology or
             urinalysis, including serum glutamic-oxaloacetic transaminase/aspartate
             aminotransferase or serum glutamic pyruvic transaminase/alanine aminotransferase ≥3
             times the upper limit of the reference range or a serum creatinine &gt;2 mg/dL at
             screening.

         13. Have severe enough psychiatric or substance abuse disorder to compromise the subject's
             safety or scientific integrity of the study.

         14. Have on-going litigation associated with back pain or pending applications for workers
             compensation or disability issues or subjects who plan on filing litigation or claims
             within the next 12 months; subjects with settled past litigations will be allowed as
             will subjects who have been on workers compensation or disability claims for at least
             3 months.

         15. Have used a monoamine oxidase inhibitor within 14 days prior to the start of study
             medication.

         16. Are taking agonist-antagonists (pentazocine, butorphanol or nalbuphine),
             buprenorphine, methadone, barbiturates, or more than one type of benzodiazepine within
             1 month prior to screening.

         17. Have a positive UDT for illicit drugs (including marijuana), non-prescribed controlled
             substances (opioid or non-opioid), or alcohol at screening.

         18. Have taken any investigational drug within 30 days prior to the Screening Visit or are
             currently enrolled in another investigational drug study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Member Companies of the Opioid PMR Consortium</last_name>
    <phone>888.969.3775</phone>
    <email>CTinfo@opcstudy.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>G &amp; L Research</name>
      <address>
        <city>Foley</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Horizon Research Partners</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Healthscan Clinical Trials</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Pain and Supportive Care</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Pain Center of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quality of Life Medical and Research Centers</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Pain and Spinal Diagnostics</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aviva Research</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Global Clinical Trials</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Helm Center for Pain Management</name>
      <address>
        <city>Laguna Woods</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alexander Ford, MD</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samaritan Center for Medical Research</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Country Clinical Research</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westview Clinical Research</name>
      <address>
        <city>Placentia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Foothills Pain Management Clinic</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern California Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Breakthrough Clinical Trials</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Optimus Medical Group</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mountain View Clinical Research</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Care Research Center</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Direct Helpers Research Center</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Finlay Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Future Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Florida Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Martin E Hale, MD</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Medical Pain Management</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgia Institute for Clinical Research</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sestron Clinical Research</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network II</name>
      <address>
        <city>Blue Island</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana Pain and Spine Clinic</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid-American Psysiatrists</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>WK River Cities Clinical Research Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedVadis Research Corporation</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oakland Medical Research</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Network</name>
      <address>
        <city>Hazelwood</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Louis Clinical Trials</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Red Rock Clinical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OnSite Clinical Solutions</name>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prestige Clinical Research</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Star Medical Research</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cutting Edge Research Group</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Research International</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SP Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brandywine Clinical Research</name>
      <address>
        <city>Downingtown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Founders Research Corporation</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carolina Center for Advanced Management of Pain</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Healthy Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Pain Specialists</name>
      <address>
        <city>Hendersonville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Phase Research and Development</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Biopharma Informatic Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Medical Group</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Highland Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Interventional Pain and Spine Specialists</name>
      <address>
        <city>Chester</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Healing Hands of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Member Companies Opioid PMR Consortium</last_name>
      <phone>888-969-3775</phone>
      <email>CTinfo@opcstudy.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2016</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Oxymorphone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

